Business Wire2d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patient…
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
CEL-SCI announces neoadjuvant nivolumab plus chemotherapy study published
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Yahoo Finance3d
CEL-SCI Corporation (CVM)
VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial. VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows ...
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.
Business Wire24d
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte ...
Arcellx on Redefining CAR-T Therapy: Vanguards of Health Care
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Targeted Oncology3d
BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...